OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Experts Examine the Future of Active Immunotherapy in Oncology and the potential role of Adagloxad Simolenin (OBI-822) TAIPEI, TAIWAN, September 6, 2016 – OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that it will host an industry-sponsored satellite symposium at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting in Copenhagen, […]